Content variability of active drug substance in compounded oral 3,4-diaminopyridine products

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 1, 2012, Pages 53-57

  Green, D M ^a   Jones, A C ^a   Brain, K R ^a,b  

^a An eX Analytical Services Ltd   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

drug information; formulation; pharmacy; quality

Indexed keywords

3,4 DIAMINOPYRIDINE;

ARTICLE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG IMPURITY; DRUG INFORMATION; DRUG ISOLATION; DRUG LABELING; EUROPE; GOOD MANUFACTURING PRACTICE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UNITED STATES; WEIGHT;

4-AMINOPYRIDINE; ADMINISTRATION, ORAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG CONTAMINATION; DRUG LABELING; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; POTASSIUM CHANNEL BLOCKERS; QUALITY CONTROL;

EID: 84856342198     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01249.x     Document Type: Article

References (23)

1. Orphanet: Lambert-Eaton Myasthnic Syndrome (2010) Available at: (last accessed 5 October 2010).
2. Wirtz PW, van Dijk JG, van Doorn PA, et al. The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology, 2004; 63: 397-398. (Pubitemid 38971159)
3. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. Journal of Neurology, 2003; 250: 698-701. (Pubitemid 36718358)
4. Thomsen RH, Wilson DF, Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. Journal of Pharmacology and Experimental Therapeutics, 1983; 227: 260-265. (Pubitemid 14205298)
5. Lemeignan M, Millart H, Lamiable D, Molgo J, Lechat P, Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Research, 1984; 304: 166-169. (Pubitemid 14123328)
6. Murray NMF, Newsom-Davis J, Karni Y, Wiles CM, Oral 3,4-diaminopyridine in the treatment of the Lambert-Eaton myasthenic syndrome (LEMS). Proceedings of the meeting of the Association of British Neurologists held jointly with the Polish Neurological Society in London, April 1984. Journal of Neurology, Neurosurgery & Psychiatry, 1984; 47: 1052-1056.
7. McEvoy KM, Windebank AJ, Daube JR, Low PA, 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. New England Journal of Medicine, 1989; 321: 1567-1571. (Pubitemid 20008235)
8. Sanders DB, Howard JF Jr, Massey JM, 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis. Annals of the New York Academy of Sciences, 1993; 681: 588-590. (Pubitemid 23233886)
9. Sanders DB, Massey JM, Sanders LL, Edwards LJ, A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology, 2000; 54: 603-607. (Pubitemid 30082925)
10. Oh SJ, Claussen GG, Hatanaka Y, Morgan MB, 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle and Nerve, 2009; 40: 795-800.
11. Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clinical Pharmacology & Therapeutics, 2009; 86: 44-48.
12. Quartel A, Turbeville S, Lounsbury D, Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Current Medical Research and Opinion, 2010; 26: 1363-1375.
13. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. European Journal of Neurology, 2006; 13: 682-690. (Pubitemid 44139368)
14. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology, 2006; 13: 691-699. (Pubitemid 44139369)
15. Raust JA, Goulay-Dufaÿ S, Le Hoang MD, Pradeau D, Guyon F, Do B, Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2007; 43: 83-88. (Pubitemid 44856820)
16. The Council of the European Communities (1975) Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products. Available at: (Last accessed 21 February 2011).
17. Do B, Goulay-Dufaÿ S, Le Hoang MD, Raust JA, Guyon F, Graffard H, Pradeau D, HPLC method for determination of 3,4-diaminopyridine in the presence of related substances and degradation products formed under stress conditions. Chromatographia, 2006; 63: 599-603. (Pubitemid 43893015)
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Limited FDA survey of compounded drug products. Available at: (last accessed 21 February 2011).
19. Burton JM, Bell CM, Walker SE, O'Connor PW, 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology, 2008; 71: 1833-1834.
20. Schwam E, Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. The Journal of Emergency Medicine, doi:.
21. Commission of the European Communities Commission decision of 18/12/2002 relating to the designation of medicinal product "3,4-diaminopyridine phosphate" as an orphan medicinal product. Brussels: C(2002)5445.
22. Committee for Medicinal Products for Human Use Committee for medicinal products for human use summary of positive opinion for ZENAS, International Nonproprietary Name (INN): amifampridine. London: EMEA/CHMP/655953/2009.
23. Firdapse Summary of Product Characteristics (2010) Available at: (last accessed 21 February 2011).